OS Therapies Incorporated (OSTX)
NYSE: OSTX · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2019
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 31, 2026 | Mar 31, 2025 | · | · |
| Research and development | 16,360,725 | 2,839,060 | 3,216,933 | · |
| General and administrative | 12,344,976 | 3,974,786 | 1,125,712 | · |
| Operating income | -28,705,701 | -6,813,846 | -4,342,645 | · |
| Interest expense | · | 2,051,839 | 3,448,939 | · |
| Interest and investment income | 249 | · | 2 | · |
| Total non-operating income (expense) | -48,143 | -2,069,092 | -3,448,937 | · |
| Net income | -28,753,844 | -8,882,938 | -7,791,582 | · |
| Net income to common shareholders | -28,753,844 | -8,914,188r | -7,916,582 | · |
| Earnings per share, basic | -0.98 | -1.28r | -1.46 | · |
| Earnings per share, diluted | -0.98 | -1.28r | -1.46 | · |
| Weighted average shares, basic | · | 12,377,299 | 5,429,248 | · |
| Weighted average shares, diluted | 29,253,292 | 6,950,100 | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding